New data show that health spending over the past several years has been normalizing toward the rate of general inflation, rather than growing higher and higher, as had been the case almost continuously since the 1970s.

This monograph demonstrates empirically how the free-market system of drug pricing is vital to the development of new breakthrough drugs.

Pharmaceutical research has generated a string of breakthrough drugs, saving millions of lives and drastically improving quality of life. Ongoing research promises more innovation in the next decade. But miracle drugs raise difficult issues in pricing, especially in developing nations.

Drug manufacturers charge much lower prices in developing nations...

The cost of developing drugs is rising at an unsustainable pace, new company formation in the biotech sector has dwindled, and healthcare costs continue to rise. We must craft policies that provide the proper incentives for new technology while making sure that we are getting more value for programs like Medicare.

Two decades ago, European firms dominated the world pharmaceutical market, just as they had for most of the twentieth century. Now, with a few notable exceptions, the market is dominated by American firms. U.S.-based companies account for most of the worldwide bestselling drugs and for most newly introduced breakthrough drugs--especially...

Even comparative effectiveness proposals will hamper new drug development.

Creating price controls on pharmaceuticals could stifle the development of new breakthrough drugs.

Controversies surrounding pharmaceutical patents and trade rules in the WTO

Pharmaceutical patents, drug prices, and parallel imports of drugs from lower-income to higher-income nations have been at the center of some of the most contentious debates in the run-up to Cancun. This panel will analyze the positions of the various protagonists...